Biodegradable Polymers and Stents: the Next Generation?

  • Guilly Rebagay
  • Sripal BangaloreEmail author
Secondary Prevention and Intervention (D. Steinberg, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Secondary Prevention and Intervention


Purpose of Review

Stent design continues to evolve with newer generation of stents aimed at improving clinical outcomes. This review compares different generations of stents with a focus on biodegradable polymers and stents and their potential benefits.

Recent Findings

Drug-eluting stents (DES) reduce stent thrombosis when compared with bare-metal stents (BMS). However, they are associated with impaired vascular healing/endothelialization and excess very long-term events (beyond 1 year). Much of these events (beyond 1 year) have been attributed to continued inflammation due to the polymer. Biodegradable-polymer drug-eluting stents (BP DES) were designed to overcome this polymer related limitation of first-generation DP DES by combining the benefits of reduced in-stent restenosis seen with DES and the benefits of reduced very-late stent thrombosis and myocardial infarction due to absence of polymer with bare-metal stents (BMS). Earlier generation of BP DES showed superiority over first-generation DP DES but at best non-inferior to second-generation DP DES for clinical outcomes; however, the newer-generation BP DES with ultrathin struts show promise in further reducing clinical outcomes when compared with second-generation DP DES. Whether this is due to the biodegradable polymer or the ultrathin struts continues to be debated.


Biodegradable polymer stents in conjunction with ultrathin struts have shown promise as the next generation of DES; however, additional studies and long-term follow-up are needed to confirm these effects.


Biodegradable polymer stent Ultrathin struts Restenosis 


Compliance with Ethical Standards

Conflict of Interest

Dr. Rebagay: None; Dr. Bangalore: Advisory board/Honoraria: Abbott Vascular, Biotronix, Amgen, Pfizer, AstraZeneca, Menarini, Reata; Research grants: Abbott Vascular, NHLBI.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Organization WH. Global health estimates 2016: disease burden by cause, age, sex, by country and by region, 2000–2016. 2018.
  2. 2.
    Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med. 1994;331:489–95. Scholar
  3. 3.
    Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med. 1994;331:496–501. Scholar
  4. 4.
    Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–23. Scholar
  5. 5.
    Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, et al. Investigators T-I. Outcomes with the polymer-based paclitaxel-eluting taxus stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1172–9.CrossRefGoogle Scholar
  6. 6.
    Lagerqvist B, Carlsson J, Frobert O, Lindback J, Schersten F, Stenestrand U, et al. Stent thrombosis in Sweden: a report from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv. 2009;2:401–8. Scholar
  7. 7.
    Rathore S, Terashima M, Suzuki T. Late-acquired stent malapposition after sirolimus-eluting stent implantation following acute coronary syndrome: angiographic, ivus, oct and coronary angioscopic observation. J Invasive Cardiol. 2009;21:666–7.PubMedGoogle Scholar
  8. 8.
    Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400–9. Scholar
  9. 9.
    Sarno G, Lagerqvist B, Frobert O, Nilsson J, Olivecrona G, Omerovic E, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography And Angioplasty Registry (SCAAR). Eur Heart J. 2012;33:606–13. Scholar
  10. 10.
    Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125:1110–21. Scholar
  11. 11.
    • Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease. Circulation. 2019;139:325–33. Kufner et al. demonstrate 10-year follow-up results of a randomized clinical trial of 2603 patients comparing three stents (a second-generation BP DES, a first-generation DP DES, and a second-generation DP DES) showing a significant reduction in the composite outcome of death, MI, and TLR with BP DES compared with first-generation DP DES, however non-inferiority between BP DES and second-genration DP DES. This study showed both long-term efficacy and safety data for BP DES. Scholar
  12. 12.
    Waksman R, Maluenda G. Polymer drug-eluting stents: is the future biodegradable? Lancet. 2011;378:1900–2. Scholar
  13. 13.
    Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, et al. Randomized comparison of the Nobori biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in Patients with stenosis in native coronary arteries: The NOBORI 1 trial--phase 2. Circ Cardiovasc Interv. 2009;2:188–95. Scholar
  14. 14.
    Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN, et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet. 2013;381:661–9. Scholar
  15. 15.
    Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the leaders (limus eluted from a durable versus erodable stent coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013;6:777–89.CrossRefGoogle Scholar
  16. 16.
    Smits PC, Hofma S, Togni M, Vazquez N, Valdes M, Voudris V, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet. 2013;381:651–60. Scholar
  17. 17.
    Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, Feldman RL, Stein B, Dubois C, Grady T, Saito S, Kimura T, Christen T, Allocco DJ, Dawkins KD. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the evolve ii randomized trial. Circ Cardiovasc Interv 2015;8,
  18. 18.
    •• Kandzari DE, Koolen JJ, Doros G, Massaro JJ, Garcia-Garcia HM, Bennett J, et al. Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents. J Am Coll Cardiol. 2018;72:3287–97. Kandzari et al. demonstrated 2-year follow-up results of a randomized control trial of 1334 patients comparing ultrathin-strut BP DES with contemporary second-generation DP DES showing significant reduction in the primary endpoint of target lesion failure with BP DES (7.5% vs 11.9 %) driven primarily by target vessel–related MI and ischemia-driven TLR and a significant reduction in definite late/very-late stent thrombosis. This study showed that ultrathin-strut platforms with bioabsorpable polymers had significant clinical benefit over contemporary second-generation durable polymer, thicker strut DES. Scholar
  19. 19.
    Roguin A, Kandzari DE, Marcusohn E, Koolen JJ, Doros G, Massaro JM, et al. Subgroup analysis comparing ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in acute coronary syndrome patients. Circ Cardiovasc Interv. 2018;11:e007331. Scholar
  20. 20.
    •• Bangalore S, Toklu B, Patel N, Feit F, Stone GW. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease. Circulation. 2018;138:2216–26. Bangalore et al. demonstrated in this meta-analysis of 10 trials that randomized 11,658 patients to either ultrathin-strut DES (strut thickness < 70 μm) or contemporary thicker strut second-generation DES that ultrathin-strut DES was associated with a significant 16% reduction in TLF driven primarily by less MI and also a trend towards a reduction in stent thrombosis after 1-year follow-up. This study was the largest meta-analysis to demonstrate improved clinical outcomes with ultrathin-strut DES compared with contemporary thicker strut DES. Scholar
  21. 21.
    Cassese S, Xhepa E, Ndrepepa G, Kufner S, Colleran R, Giacoppo D, et al. Vascular response to percutaneous coronary intervention with biodegradable-polymer vs. new-generation durable-polymer drug-eluting stents: a meta-analysis of optical coherence tomography imaging trials. Eur Heart J Cardiovasc Imaging. 2018;19:1294–301. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.New York University School of MedicineNew YorkUSA
  2. 2.Complex Coronary Intervention (Bellevue), Cardiac Catheterization Laboratory, Cardiovascular Outcomes Group, The Leon H. Charney Division of CardiologyNew York University School of MedicineNew YorkUSA

Personalised recommendations